Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for TWAPF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TWAPF and 80,000+ other tickers.
See exactly how TWAPF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TWAPF and 80,000+ other tickers.
Operating in Japan, Towa Pharmaceutical Co., Ltd. and its subsidiaries are engaged in the research, development, production, and sale of prescription drugs, active pharmaceutical ingredients, and intermediates. The company's extensive portfolio addresses critical therapeutic areas such as diabetes, digestive health, neurological conditions, and allergic diseases, alongside offering vitamins, antibiotics, and oncology treatments. With approximately 700 different drug products, Towa Pharmaceutical Co., Ltd. was established in 1951 and is headquartered in Osaka, Japan.
